Wells Fargo analyst David Maris lowered his price target on Ironwood (IRWD) to $18.50 after the Allergan (AGN) Q3 results lowered expectations for their jointly produced Linzess product. The analyst notes that the management of Ironwood also subsequently confirmed its base case sales growth of low single digits, also lowering his FY19 EPS view to 63c from 69c. Longer term, Maris keeps his Outperform rating, saying the recent share decline should make the board revisit its strategic review and question whether the company is better off being independent.